scholarly journals Nigella sativa L. as a Potential Phytotherapy for COVID-19: A Mini-Review of In-silico Studies

2020 ◽  
Author(s):  
Abdulrahman E. Koshak ◽  
Emad A. Koshak
Keyword(s):  
Infectious Disease ◽  
Clinical Trials ◽  
Severe Acute Respiratory Syndrome ◽  
Literature Review ◽  
Preliminary Data ◽  
In Silico ◽  
Nigella Sativa ◽  
Antiviral Agent ◽  
Antiviral Compounds ◽  
In Silico Studies

Coronaviruses are responsible for several human diseases such as the pandemic infectious disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). So far, there is no effective approved antiviral agent for SARS-CoV-2. Natural products, such as Nigella sativa (NS), provide a wealth of known antiviral compounds. This mini literature review was aimed to explore any published or preprint in-silico data on the binding affinity of NS compounds to SARS-CoV-2 targets. At least eight in-silico studies have shown that some compounds of NS, including Nigelledine, α- Hederin, Hederagenin, Thymohydroquinone, Thymoquinone, had high to moderate affinity with SARS-CoV-2 enzymes and proteins. These compounds might potentially inhibit SARS-CoV-2 replication and attachment to host cell receptors. These preliminary data proposes NS as a potential phytotherapy candidate in clinical trials for COVID-19.

scholarly journals Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)

2020 ◽  
Vol 64 (12) ◽  
Author(s):  
Peter A. McCullough
Keyword(s):  
Clinical Trials ◽  
Drug Therapy ◽  
Severe Acute Respiratory Syndrome ◽  
Viral Infections ◽  
Antiviral Agent ◽  
Advanced Practice ◽  
Ambulatory Treatment ◽  
Nasal Secretions ◽  
Polymerase Inhibitor ◽  
Multiple Drugs

ABSTRACT It is becoming increasingly clear that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), like most human viral infections, will require multiple drugs in combination to treat COVID-19 illness. In this issue of the Journal, Doi and colleagues describe successful treatment of patients with early COVID-19 with favipiravir, an oral polymerase inhibitor, to rapidly and substantially clear SARS-CoV-2 from nasal secretions irrespective if it was started relatively early or later within the first week of infection. These data support the concept that favipiravir could be paired with at least one more off-target antiviral agent (doxycycline, azithromycin, or ivermectin) followed by corticosteroids and antithrombotics to prevent COVID-19 hospitalization and death in those over age 50 and/or those with one or more comorbidities. Clinical trials and advanced practice should immediately pivot to combination/sequential drug therapy for ambulatory COVID-19 illness.

scholarly journals Current Potential Antiviral Agents for Coronavirus Disease 2019 (COVID-19) Therapy

2020 ◽  
Vol 7 (1A) ◽  
pp. 249-252
Author(s):  
Prayogi Kramy
Keyword(s):  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Severe Acute Respiratory Syndrome ◽  
Literature Review ◽  
Respiratory Tract ◽  
Antiviral Agents ◽  
Specific Treatment ◽  
Hubei Province ◽  
Herbal Plants ◽  
Current Potential

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first discovered in Wuhan, Hubei Province, China. SARS-CoV-2 infects the respiratory tract, which causes coronavirus disease 2019 (COVID-19). Various studies have been conducted to find effective therapies. However, there is still no specific treatment or therapy for COVID-19. This literature review, summarizes some recent research on several potential antiviral agents, both drugs that are commonly used in the medical world such as ivermectin, to medicine from herbal plants and some drugs that are in the process of clinical trials such as remdesivir, lopinavir/ritonavir, Interferon ?, ribavirin, convalescent plasma, and monoclonal antibodies  for COVID-19 therapy. KEYWORDS: SARS-CoV-2, COVID-19, Antiviral Agents, Potential therapy.

scholarly journals In-silico Studies of Antimalarial-agent Artemisinin and Derivatives Portray More Potent Binding to Lys353 and Lys31-Binding Hotspots of SARS-CoV-2 Spike Protein than Hydroxychloroquine: Potential Repurposing of Artenimol for COVID-19.

2020 ◽  
Author(s):  
Moussa SEHAILIA ◽  
Smain chemat
Keyword(s):  
Clinical Trials ◽  
In Silico ◽  
Spike Protein ◽  
Antimalarial Agent ◽  
In Silico Studies ◽  
Better Than

<p>The role of hydroxychloroquine to prevent hACE2 from interacting with SARS-CoV-2 Spike protein is unveiled. Artemisinin & derived compounds entangle better than hydroxychloroquine into Lys353 and Lys31 binding hotspots of the virus Spike protein, therefore preventing infection occurs. Since these molecules are effective antivirals with excellent safety track records, their potential repurposing is recommended for clinical trials of COVID-19 patients.</p>

scholarly journals Convalescent Plasma Therapy: a Possible Treatment of COVID-19 Pandemic

2020 ◽  
Vol 2 (2) ◽  
pp. 45-47
Author(s):  
Shubha Devi Sapkota ◽  
Monika Sharma ◽  
Gehendra Bhusal
Keyword(s):  
Infectious Disease ◽  
Clinical Trials ◽  
Severe Acute Respiratory Syndrome ◽  
Large Scale ◽  
Alternative Therapy ◽  
Lung Damage ◽  
Plasma Therapy ◽  
The Past ◽  
Wide Range ◽  
Severe Infections

COVID 19 is a newly recognized infectious disease that has rapidly spread with no verified treatment available. It is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). In Convalescent plasma therapy, the yellowish liquid or the plasma from the recovered blood is used to treat the patient suffering from the same illness. For more than 100 years it has been used to treat severe infections with varying degrees of success. For this present infection, multiple clinical trials on plasma therapy are still under vigorous investigations. Despite the very low chance of risks like allergies, lung damage, and transmission of blood-related infection, the therapy has shown a positive result in the recovery of the patients. Many experts are observing its use as a “stopgap measure” until effective vaccines and antiviral drugs are available in a wide range. However, the main challenges faced are finding suitable donors, its expensiveness in the whole procedure, and inability to perform on a large scale. In this commentary, summarization of the convalescent plasma therapy is done as a hopeful alternative therapy of severe or critical COVID 19. It has also emphasized the promising results shown since the past while the use of this therapy in various infectious diseases.

scholarly journals In silico Studies of Novel Synthetic Compounds as Potential Drugs to Inhibit Coronavirus (SARS-CoV-2): A Systematic Review

2021 ◽  
Vol 12 (4) ◽  
pp. 4293-4306
Keyword(s):  
Systematic Review ◽  
Severe Acute Respiratory Syndrome ◽  
In Silico ◽  
Drug Target ◽  
Computational Studies ◽  
Pharmacological Treatments ◽  
Synthetic Compounds ◽  
In Silico Studies ◽  
The World ◽  
Molecule Interaction

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), detected first in China, spread out fast to other parts of the world, and was soon recognized as a pandemic in March 2020. According to WHO, 179.686.071 confirmed cases and 3.899.172 deaths due to new coronavirus were reported worldwide on 26th June 2021. Despite countless efforts in searching for repositioned drugs to treat this disease, the results are still modest. Thus, the search for new molecular entities in the treatment of COVID-19 is an essential field in medicinal chemistry. Since the pandemic's beginning, several studies have reported the synthesis of novel organic compounds and their in silico interactions with the new coronavirus. Such computational studies are currently being applied to unveil the complexities of drug-target molecule interaction and also helping in developing new pharmacological treatments. This systematic review aims to provide an overview of studies describing the utilization of novel compounds as prospective drugs in the treatment of COVID-19.

scholarly journals DOES HEPARIN HAVE AN ESSENTIAL ROLE IN THE TREATMENT OF THE COVID-19 PANDEMIC? A REVIEW

2021 ◽  
Vol 3 (1) ◽  
pp. 374-385
Keyword(s):  
Infectious Disease ◽  
Clinical Trials ◽  
Severe Acute Respiratory Syndrome ◽  
Prothrombin Time ◽  
Inflammatory Mediators ◽  
Observational Studies ◽  
Essential Role ◽  
Clinical Manifestations ◽  
Efficacy And Safety ◽  
Plasma Markers

Coronavirus 2019 (COVID-19), is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first reported in December 2019. The plasma markers of coagulation, like D-dimers and elevated prothrombin time (PT) are higher in patients with COVID-19. The administration of anticoagulant is beneficial in those patients. Heparins have many therapeutic functions that are important for the controlling of COVID-19-associated clinical manifestations like, neutralization of inflammatory mediators and neutralization of extracellular cytotoxic histones. Many observational studies in different countries have been done and large number of clinical trials have been designed and registered to evaluate efficacy and safety of heparin for patients with COVID-19. The aim of this narrative review is to summarize all available data from previously published studies concerning the use of heparin in treatment of the COVID-19 pandemic.

scholarly journals PADRÃO DE OCLUSÃO EM PRÓTESE TOTAL: UM DILEMA DA REABILITAÇÃO ORAL

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Priscylla Lima Frota ◽  
Poliana Lima Bastos ◽  
Viviane Maria Gonçalves de Figueiredo
Keyword(s):  
Clinical Trials ◽  
Literature Review ◽  
Muscle Activity ◽  
In Silico ◽  
Relevant Literature ◽  
Google Scholar ◽  
Oral Rehabilitation ◽  
Advantages And Disadvantages ◽  
Literature Reviews ◽  
The Stability

Choosing occlusion standards in dentures is a dilemma in oral rehabilitation, as it raises questions on which standard the dentist should use. This decision may influence the stability of the denture. Based on this problem, a literature review with articles published in the last five years, in search engines Pubmed.gov, Google Scholar and Scielo was performed. The keywords Prosthodontics, Occlusion and Edentulism were used. In this review, the articles on clinical trials and studies in silico, as well as relevant literature reviews were included. Although often the dentist may be resistant to use another type of occlusal pattern than balanced occlusion, it is important to emphasize advantages and disadvantages of occlusal arrangements in order to slow the residual ridge resorption and decrease muscle activity.

scholarly journals In-silico Studies of Antimalarial-agent Artemisinin and Derivatives Portray More Potent Binding to Lys353 and Lys31-Binding Hotspots of SARS-CoV-2 Spike Protein than Hydroxychloroquine: Potential Repurposing of Artenimol for COVID-19.

2020 ◽  
Author(s):  
Moussa SEHAILIA ◽  
Smain chemat
Keyword(s):  
Clinical Trials ◽  
In Silico ◽  
Spike Protein ◽  
Antimalarial Agent ◽  
In Silico Studies ◽  
Better Than

<p>The role of hydroxychloroquine to prevent hACE2 from interacting with SARS-CoV-2 Spike protein is unveiled. Artemisinin & derived compounds entangle better than hydroxychloroquine into Lys353 and Lys31 binding hotspots of the virus Spike protein, therefore preventing infection occurs. Since these molecules are effective antivirals with excellent safety track records, their potential repurposing is recommended for clinical trials of COVID-19 patients.</p>

scholarly journals Food and COVID-19: Preventive/Co-therapeutic Strategies Explored by Current Clinical Trials and in Silico Studies

Foods ◽  
2020 ◽  
Vol 9 (8) ◽  
pp. 1036 ◽  
Author(s):  
Giacomo Di Matteo ◽  
Mattia Spano ◽  
Michela Grosso ◽  
Andrea Salvo ◽  
Cinzia Ingallina ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Immune System ◽  
In Silico ◽  
Therapeutic Strategies ◽  
Bioactive Molecules ◽  
Potential Contribution ◽  
Food Ingredients ◽  
In Silico Studies ◽  
Functional Components

Foods, food ingredients, and their balanced consumption are recognized to have an important role in achieving or maintaining a state of wellbeing by acting as carriers of functional components and bioactive molecules. However, the potential contribution of foods to consumers’ health has so far only been partially exploited. The rapidly evolving scenario of the coronavirus disease 2019 (COVID-19) pandemic is stimulating profound reflection on the relationships between food and the etiological agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, the status of knowledge regarding food as a possible defense/co-therapeutic strategy against the SARS-CoV-2 coronavirus is considered through the discussion of two main current lines of research. One line of research relates to the role of micronutrients, food components, and diets in the strengthening of the immune system through clinical trials; formulations could be developed as immune system enhancers or as co-adjuvants in therapies. The other line of research relates to investigation of the chemical interactions that specific food compounds can have with host or virus targets so as to interfere with the viral infective cycle of SARS-CoV-2. This line requires, as a first step, an in silico evaluation to discover lead compounds, which may be further developed through drug-design studies, in vitro and in vivo tests, and, finally, clinical trials to obtain therapeutic molecules. All of these promising strategies promote the role of food in preventive/co-therapeutic strategies to tackle the COVID-19 pandemic.

Sign in / Sign up

Export Citation Format

Share Document